Phospho-tau antibodies and methods of use
AssigneeAlzpath, Inc.
InventorsAndreas Jeromin, Krish Venkat
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Claims72
An anti-tau antibody or antigen binding fragment thereof comprising:
- a heavy chain comprising a variable heavy chain (VH) domain;
- and
- a light chain comprising a variable light chain (VL) domain, wherein:
- the VH domain comprises HCDR1 sequence comprising SEQ ID NO:
- 2, HCDR2 sequence comprising SEQ ID NO:
- 7, and HCDR3 sequence comprising SEQ ID NO:
- 11;
- and
- the VL domain comprises LCDR1 sequence comprising SEQ ID NO:
- 15, LCDR2 sequence comprising SEQ ID NO:
- 21, and LCDR3 sequence comprising SEQ ID NO:
- 25.
An anti-tau antibody or antigen binding fragment thereof comprising:
- a heavy chain comprising a variable heavy chain (VH) domain;
- and
- a light chain comprising a variable light chain (VL) domain, wherein:
- the VH domain comprises HCDR1 sequence comprising SEQ ID NO:
- 4, HCDR2 sequence comprising SEQ ID NO:
- 7, and HCDR3 sequence comprising SEQ ID NO:
- 12;
- and
- the VL domain comprises LCDR1 sequence comprising SEQ ID NO:
- 18, LCDR2 sequence comprising SEQ ID NO:
- 23, and LCDR3 sequence comprising SEQ ID NO:
- 28.
An anti-tau antibody or antigen binding fragment thereof comprising:
- a heavy chain comprising a variable heavy chain (VH) domain;
- and
- a light chain comprising a variable light chain (VL) domain, wherein:
- the VH domain comprises HCDR1 sequence comprising SEQ ID NO:
- 5, HCDR2 sequence comprising SEQ ID NO:
- 9, and HCDR3 sequence comprising SEQ ID NO:
- 13;
- and
- the VL domain comprises LCDR1 sequence comprising SEQ ID NO:
- 19, LCDR2 sequence comprising SEQ ID NO:
- 21, and LCDR3 sequence comprising SEQ ID NO:
- 29.
An anti-tau antibody or antigen binding fragment thereof comprising:
- a heavy chain comprising a variable heavy chain (VH) domain;
- and
- a light chain comprising a variable light chain (VL) domain, wherein:
- the VH domain comprises HCDR1 sequence comprising SEQ ID NO:
- 1, HCDR2 sequence comprising SEQ ID NO:
- 6, and HCDR3 sequence comprising SEQ ID NO:
- 10;
- and
- the VL domain comprises LCDR1 sequence comprising SEQ ID NO:
- 14, LCDR2 sequence comprising SEQ ID NO:
- 20, and LCDR3 sequence comprising SEQ ID NO:
- 24.
An anti-tau antibody or antigen binding fragment thereof comprising:
- a heavy chain comprising a variable heavy chain (VH) domain;
- and
- a light chain comprising a variable light chain (VL) domain, wherein:
- the VH domain comprises HCDR1 sequence comprising SEQ ID NO:
- 2, HCDR2 sequence comprising SEQ ID NO:
- 7, and HCDR3 sequence comprising SEQ ID NO:
- 11;
- and
- the VL domain comprises LCDR1 sequence comprising SEQ ID NO:
- 16, LCDR2 sequence comprising SEQ ID NO:
- 22, and LCDR3 sequence comprising SEQ ID NO:
- 26.
An anti-tau antibody or antigen binding fragment thereof comprising:
- a heavy chain comprising a variable heavy chain (VH) domain;
- and
- a light chain comprising a variable light chain (VL) domain, wherein:
- the VH domain comprises HCDR1 sequence comprising SEQ ID NO:
- 3, HCDR2 sequence comprising SEQ ID NO:
- 8, and HCDR3 sequence comprising SEQ ID NO:
- 10;
- and
- the VL domain comprises LCDR1 sequence comprising SEQ ID NO:
- 17, LCDR2 sequence comprising SEQ ID NO:
- 20, and LCDR3 sequence comprising SEQ ID NO:
- 27.
Dependencies are inferred from the claim text.